Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
(NPR/Shots blog) Aug 16, 2018 - Aaron Reid is lying in a hospital bed at the National Institutes of Health when doctors arrive to make sure he's ready for his experimental treatment.
"How's your night? Any issues?" asks Dr. Katherine Barnett, a pediatric oncologist, as they begin to examine Reid.
Reid, 20, of Lucedale, Miss., has...
(Daiichi Sankyo) Aug 1, 2018 - Daiichi Sankyo Company, Limited announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML).